Skip to main content
Clinical Trials/NCT05578196
NCT05578196RecruitingNot Applicable

Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections:A Randomized Clinical Trial

Shanghai 10th People's Hospital1 site in 1 country110 target enrollmentStarted: September 4, 2022Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
110
Locations
1
Primary Endpoint
Death

Study Overview

Brief Summary

Fecal microbial transplantation is to transplant functional microbiota from the feces of healthy people into the gastrointestinal tract of patients, reconstruct new intestinal microbiota, and realize the treatment of intestinal and extra-intestinal diseases. Compared with ordinary commercial probiotics, FMT is more consistent with the composition of the intestinal microecological structure and can recover intestinal flora to the maximum extent and faster. FMT increases intestinal bacteria production function and helps to restore the systemic immune response so that sepsis pathogens are removed. The aim of this trial was to investigate the clinical effect of FMT in the treatment of patients with severe infections.

Detailed Description

The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
14 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients diagnosed with severe infections, which is infected patients SAFA≥2 OR APACHE Ⅱ≥15
  • Aged ≥14 years
  • Patients or their family members agreed to participate in this study

Exclusion Criteria

  • Advanced tumors or diseases associated with systemic immunosuppression
  • Pregnant women
  • Patients with severe intestinal ulcer or perforation
  • Unable to complete oral administration and no effective artificial feeding pipeline.

Arms & Interventions

The experimental group with FMT

Experimental

The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group

Intervention: fecal bacteria solution (Drug)

The control group with physiological saline

Other

The gastrointestinal tube access was established, and the standard preparation of physiological saline solution 20ml

Intervention: physiological saline solution (Drug)

Outcomes

Primary Outcomes

Death

Time Frame: up to 28 days in ICU

Clinical outcome

Secondary Outcomes

  • Gut microbiota distribution assessed by 16SrDNA(up to 6 days after fecal microbial transplantation)

Investigators

Sponsor
Shanghai 10th People's Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Chen Yuanzhuo

associate chief physician

Shanghai 10th People's Hospital

Study Sites (1)

Loading locations...

Similar Trials